These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 28199309)

  • 1. Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.
    Compagno M; Wang Q; Pighi C; Cheong TC; Meng FL; Poggio T; Yeap LS; Karaca E; Blasco RB; Langellotto F; Ambrogio C; Voena C; Wiestner A; Kasar SN; Brown JR; Sun J; Wu CJ; Gostissa M; Alt FW; Chiarle R
    Nature; 2017 Feb; 542(7642):489-493. PubMed ID: 28199309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
    Till KJ; Pettitt AR; Slupsky JR
    J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
    Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
    PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
    Lampson BL; Brown JR
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A
    Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and function of phosphoinositide 3-kinase delta in mesenchymal stromal cells from normal and leukaemic bone marrow.
    Ali AY; Guan Q; Wu X; Hou S; Banerji V; Johnston JB; Wall D; Szwajcer D; Gibson SB; Marshall AJ
    Br J Haematol; 2019 Jun; 185(5):883-887. PubMed ID: 30873593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Inhibition of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110
    Alfaro J; Pérez de Arce F; Belmar S; Fuentealba G; Avila P; Ureta G; Flores C; Acuña C; Delgado L; Gaete D; Pujala B; Barde A; Nayak AK; Upendra TVR; Patel D; Chauhan S; Sharma VK; Kanno S; Almirez RG; Hung DT; Chakravarty S; Rai R; Bernales S; Quinn KP; Pham SM; McCullagh E
    J Pharmacol Exp Ther; 2017 May; 361(2):312-321. PubMed ID: 28298527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amino-terminal phosphorylation of activation-induced cytidine deaminase suppresses c-myc/IgH translocation.
    Gazumyan A; Timachova K; Yuen G; Siden E; Di Virgilio M; Woo EM; Chait BT; Reina San-Martin B; Nussenzweig MC; McBride KM
    Mol Cell Biol; 2011 Feb; 31(3):442-9. PubMed ID: 21135131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.
    Dong S; Guinn D; Dubovsky JA; Zhong Y; Lehman A; Kutok J; Woyach JA; Byrd JC; Johnson AJ
    Blood; 2014 Dec; 124(24):3583-6. PubMed ID: 25258342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
    Burger JA; Okkenhaug K
    Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia.
    Frustaci AM; Tedeschi A; Deodato M; Zamprogna G; Cairoli R; Montillo M
    Future Oncol; 2019 Jul; 15(19):2227-2239. PubMed ID: 31137964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration.
    Ali AY; Wu X; Eissa N; Hou S; Ghia JE; Murooka TT; Banerji V; Johnston JB; Lin F; Gibson SB; Marshall AJ
    Leukemia; 2018 Sep; 32(9):1958-1969. PubMed ID: 29479062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
    Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
    Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
    [No Abstract]   [Full Text] [Related]  

  • 14. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.
    de Weerdt I; Koopmans SM; Kater AP; van Gelder M
    Haematologica; 2017 Oct; 102(10):1629-1639. PubMed ID: 28775119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia.
    Morande PE; Sivina M; Uriepero A; Seija N; Berca C; Fresia P; Landoni AI; Di Noia JM; Burger JA; Oppezzo P
    Blood; 2019 May; 133(19):2056-2068. PubMed ID: 30814061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Close proximity to Igh is a contributing factor to AID-mediated translocations.
    Rocha PP; Micsinai M; Kim JR; Hewitt SL; Souza PP; Trimarchi T; Strino F; Parisi F; Kluger Y; Skok JA
    Mol Cell; 2012 Sep; 47(6):873-85. PubMed ID: 22864115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase
    Shin N; Stubbs M; Koblish H; Yue EW; Soloviev M; Douty B; Wang KH; Wang Q; Gao M; Feldman P; Yang G; Hall L; Hansbury M; O'Connor S; Leffet L; Collins R; Katiyar K; He X; Waeltz P; Collier P; Lu J; Li YL; Li Y; Liu PCC; Burn T; Covington M; Diamond S; Shuey D; Roberts A; Yeleswaram S; Hollis G; Metcalf B; Yao W; Huber R; Combs A; Newton R; Scherle P
    J Pharmacol Exp Ther; 2020 Jul; 374(1):211-222. PubMed ID: 32345620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.
    Palazzo A; Herter S; Grosmaire L; Jones R; Frey CR; Limani F; Bacac M; Umana P; Oldham RJ; Marshall MJE; Cox KL; Turaj AH; Cragg MS; Klein C; Carter MJ; Tannheimer S
    J Immunol; 2018 Apr; 200(7):2304-2312. PubMed ID: 29453281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B cell receptor inhibition as a target for CLL therapy.
    Jeyakumar D; O'Brien S
    Best Pract Res Clin Haematol; 2016 Mar; 29(1):2-14. PubMed ID: 27742069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition.
    Pepper C; Buggins AG; Jones CH; Walsby EJ; Forconi F; Pratt G; Devereux S; Stevenson FK; Fegan C
    Leukemia; 2015 Mar; 29(3):744-7. PubMed ID: 25349153
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 27.